Switch View
© PR Newswire
26.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
SAN DIEGO, Oct. 26, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), have until December 15, 2025 to seek a...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.10.2025
ISIN: US31189P1021
Fate Therapeutics Inc
FATE
LISTED
NASDAQ
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
News Preview
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy...
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
ISIN: US8753721047
Tandem Diabetes Care Inc
TNDM
LISTED
NASDAQ
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
News Preview
NEW YORK, Oct. 26, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
26.10.2025
ISIN: CNE100003F19
Wuxi Apptec Co., Ltd.
2359
LISTED
HKSE
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
News Preview
Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY;
Revenue from Continuing Operations[1]Reached RMB12.04 Billion, Up 19.7% YoY...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
26.10.2025
ISIN: HK0000145638
Beijing Tong Ren Tang Chinese Medicine Co Ltd
3613
LISTED
HKSE
Deep-Rooted in Community Caring for a Decade 'Tong Ren Tang Stroke Prevention Campaign' Debuts on Campus
News Preview
EQS Newswire / 26/10/2025 / 07:45 CET/CEST
Inaugural "Hong Kong Student Ambassador Programme for Chinese Medicine and Health Care" Graduation Ceremony Students Showcase Their Learning Outcomes HONG KONG SAR - Media OutReach Newswire - 26 October 2025 - Beijing Tong Ren Tang Chinese Medicine Company Limited ("Beijing Tong Ren Tang") (3613.HK) ......
Themefolio
Profiler
Peergroup
© BusinessWire
26.10.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
News Preview
Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data wil...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2025
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
News Preview
Gerresheimer AG: Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
Duesseldorf, October 25, 2025. Today, Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") obtained initial findings from an investigation by an external, independent law firm, which the com......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2025
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Erste Erkenntnisse einer externen unabhängigen Untersuchung zur Umsatzrealisierung aus Bill-and-Hold- Vereinbarungen im Geschäftsjahr 2024
News Preview
Gerresheimer AG: Erste Erkenntnisse einer externen unabhängigen Untersuchung zur Umsatzrealisierung aus Bill-and-Hold- Vereinbarungen im Geschäftsjahr 2024
Düsseldorf, 25. Oktober 2025. Die Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer"), hat heute erste Erkenntnisse aus einer von der Gesellschaft eingeleiteten externen, unabhängigen Untersu......
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: BE0003739530
UCB SA
UCB
LISTED
EURONEXT
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
News Preview
Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained inflammation c...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced updated data and first disclosure of results in chronic, refractory autoimmune diseases from the Phase 1 Breakfree-1 study (NCT05869955) of its investigational, autologous CD19-targeted NEX-T™ CAR T cell therapy BMS-986353 (CC-97540). The data, evaluating a total of 71 treated patients across the sy...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
News Preview
NEW YORK, Oct. 25, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf o...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: US2300311063
Cullinan Therapeutics Inc
CGEM
LISTED
NASDAQ
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
News Preview
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
25.10.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
News Preview
NASP data highlight reduction in disease burden among people living with uncontrolled gout...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: US5019761049
Kyverna Therapeutics, Inc.
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
News Preview
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: US71722W1071
Phathom Pharmaceuticals Inc
PHAT
LISTED
NASDAQ
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
News Preview
FLORHAM PARK, N.J., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (von...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: NL0011606264
Merus N.V.
MRUS
LISTED
NASDAQ
Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid
News Preview
– 100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd)...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: CNE100003PJ8
Venus Medtech Hangzhou Inc
2500
LISTED
HKSE
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
News Preview
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch
HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announc...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: CNE100003PJ8
Venus Medtech Hangzhou Inc
2500
LISTED
HKSE
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
News Preview
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch
HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter ref...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: CNE100003PJ8
Venus Medtech Hangzhou Inc
2500
LISTED
HKSE
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
News Preview
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch
HANGZHOU, China, Oct. 25, 2025 /CNW/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred t...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: US34965KAA51
Fortrea Holdings, Inc.
FTRE
LISTED
NASDAQ
Fortrea Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortrea Holdings, Inc. - FTRE
News Preview
NEW YORK and NEW ORLEANS, Oct. 24, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Fortrea Holdings, Inc. (NasdaqGS: FTRE)....
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Molina Healthcare, Inc. - MOH
News Preview
NEW YORK and NEW ORLEANS, Oct. 24, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilDecember 2, 2025 to file lead plaintiff applications in a securities class action lawsuit against Molina Heal...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
News Preview
NEW YORK and NEW ORLEANS, Oct. 24, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilNovember 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokineti...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: US29261A1007
Encompass Health Corp
EHC
LISTED
NYSE
Rosen Law Firm Encourages Encompass Health Corporation Investors to Inquire About Securities Class Action Investigation - EHC
News Preview
NEW YORK, Oct. 24, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on beh...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 24, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
News Preview
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score
, which is based on 11 key systemic disease domains, at Week 24 versus placebo...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
News Preview
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following letter to the Board of Directors of STAAR after the decision by STAAR Surgical and Alcon Inc. (SIX/NYSE:A...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2025
ISIN: US1407553072
Tvardi Therapeutics Inc
TVRD
LISTED
NASDAQ
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) resulting from allegations that Tvardi Therapeutics may have issued materially misleading business information to the investing public.
So What: If you purchased T...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US00773U2078
Adverum Biotechnologies Inc
ADVM
LISTED
NASDAQ
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
News Preview
NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquarte...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ISIN: US2036681086
Community Health Systems Inc
CYH
LISTED
NYSE
Community Health Systems Announces Definitive Agreement to Sell Three Pennsylvania Hospitals to Tenor Health Foundation
News Preview
Community Health Systems, Inc. (NYSE: CYH) announced today that certain subsidiaries of the Company have entered into a definitive agreement to sell 186-bed Regional Hospital of Scranton and 122-bed Moses Taylor Hospital in Scranton, Pennsylvania, 369-bed Wilkes-Barre General Hospital in Wilkes-Barre, Pennsylvania, and certain related businesses t...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: US86881A1007
Surgery Partners Inc
SGRY
LISTED
NASDAQ
Surgery Partners, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Details
News Preview
BRENTWOOD, Tenn., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2025 results before the market opens on Monday, November 10, 2025, to be followed by a conference call at 8:...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US28414H1032
Elanco Animal Health Inc
ELAN
LISTED
NYSE
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
News Preview
EUA to Treat Dogs for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options
First FDA emergency use authorization (EUA) ever granted for NWS in dogs
Action reinforces agency's c...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: CA45783P5085
Innocan Pharma Corporation
INNO
LISTED
CSE
Innocan Pharma to Present at the 2025 ThinkEquity Conference
News Preview
HERZLIYA, Israel and CALGARY, AB, Oct. 24, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it will be participating in The ThinkEquity Conference, taking pl...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: CA45783P5085
Innocan Pharma Corporation
INNO
LISTED
CSE
Innocan Pharma to Present at the 2025 ThinkEquity Conference
News Preview
HERZLIYA, Israel and CALGARY, AB, Oct. 24, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it will be participating in The ThinkEquity Conference, taking place Oct...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
MONDAY DEADLINE: Berger Montague Advises LifeMD, Inc. (NASDAQ: LFMD) Investors to Inquire About a Securities Fraud Class Action by October 27, 2025
News Preview
PHILADELPHIA, Oct. 24, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Clas...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: US70805E1091
Pennant Group Inc
PNTG
LISTED
NASDAQ
Pennant Announces Third Quarter 2025 Earnings Release and Call
News Preview
EAGLE, Idaho, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its third quarter 2025 financial results on Wednesday, November 5, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: US90400D1081
Ultragenyx Pharmaceutical Inc
RARE
LISTED
NASDAQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the company’s common stock to 17 newly hired non-executive o...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: IE000LK2BOB4
Mural Oncology PLC
MURA
LISTED
NASDAQ
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION ...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: US1940145022
Enovis Corp
ENOV
LISTED
NYSE
Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences
News Preview
Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Tim...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
News Preview
PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following:...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: US04335A1051
Arvinas, Inc.
ARVN
LISTED
NASDAQ
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
News Preview
– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – ...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US00773U2078
Adverum Biotechnologies Inc
ADVM
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders
News Preview
MILWAUKEE, Oct. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Adverum (Nasdaq: ADVM) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly....
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
News Preview
SAN FRANCISCO, Oct. 24, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD (LFMD) Faces Lawsuit Over Alleged Concealment of Cost and Refund Woes in Key Segments, According to Hagens Berman
News Preview
LFMD Investors with Losses Encouraged to Contact Hagens Berman Before Oct. 27th Deadline
SAN FRANCISCO, Oct. 24, 2025 /PRNewswire/ -- A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executives provided i...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ATYR Investor Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
News Preview
SAN FRANCISCO, Oct. 24, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation....
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ISIN: DE000BAY0017
Bayer AG
BAYN
LISTED
XETR
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
News Preview
Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.1 Inhibition of Substance P and Neurokin...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US74834L1008
Quest Diagnostics Inc
DGX
LISTED
NYSE
MVZ HPH führt ctDNA-Bluttest zur Krebsüberwachung in Europa ein, basierend auf der Haystack MRD®-Technologie von Quest Diagnostics®
News Preview
Bluttest zur Unterstützung der Krebsbehandlung und Überwachung von Rückfällen ist nun in einem deutschen Labor verfügbar und ermöglicht potenziell schnellere Ergebnisse
HAMBURG, Deutschland, 24. Oktober 2025 /PRNewswire/ -...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US00032Q1040
Whitehawk Therapeutics Inc
AADI
LISTED
NASDAQ
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
News Preview
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors
PTK7 expression is stable across histologic subtype, disease stage and metastatic status in high-potential indications, including...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US66737P6007
Northwest Biotherapeutics Inc
NWBO
LISTED
OTC
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
News Preview
BETHESDA, Md., Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. ("Advent") has closed. As a result of thi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ISIN: US98401F1057
Xencor Inc
XNCR
LISTED
NASDAQ
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
News Preview
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell ca...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US66737P6007
Northwest Biotherapeutics Inc
NWBO
LISTED
OTC
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
News Preview
BETHESDA, Md., Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. ("Advent") has closed. As a result of thi...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. (MOH) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Oct. 24, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH) have opportunity to lead the securities fraud class action lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
BENSALEM, Pa., Oct. 24, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA).
IF YOU ARE AN INVES...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
BENSALEM, Pa., Oct. 24, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR).
IF YOU ARE AN IN...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Law Offices of Howard G. Smith Encourages Baxter International, Inc. (BAX) Shareholders To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”). Baxter investors have until December 15, 2025 to file a lead plaintiff...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: US87164F1057
Syndax Pharmaceuticals Inc
SNDX
LISTED
NASDAQ
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
News Preview
– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation –...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ISIN: US2358511028
Danaher Corp
DHR
LISTED
NYSE
Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to shareholders.
If you currently own Danaher stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the compan...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ISIN: US09075P2048
BioXcel Therapeutics Inc
BTAI
LISTED
NASDAQ
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders.
If you currently own BioXcel stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ISIN: US05464T1043
Axsome Therapeutics Inc
AXSM
LISTED
NASDAQ
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders.
If you currently own Axsome stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to th...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: US8294011080
Sionna Therapeutics Inc
SION
LISTED
NASDAQ
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
News Preview
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
